Skip to content
Peptigraph home
Shop Peptides50% off*

How to Inject Ipamorelin: Sites, Syringes and Steps

Where to inject Ipamorelin, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medical review pendingGHRP (ghrelin receptor agonist)Updated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Ipamorelin in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

How the human trial gave it

The one human efficacy trial cited used intravenous infusions twice daily in hospital inpatients, not subcutaneous self-injection.[6]

That trial was run in a hospital setting.[6]

Routes used in rats

In rats, ipamorelin was injected subcutaneously three times daily for 15 days. This is animal data and says nothing about human technique.[7]

In another rat study it was given continuously by subcutaneous osmotic minipump for 12 weeks.[8]

A third rat study gave it by subcutaneous injection three times daily for 3 months alongside a glucocorticoid.[9]

No label

No Drugs@FDA product exists for ipamorelin as of 2026-10-02, so there is no labelled injection site, rotation or pen instruction.[10]

Common questions

Where do you inject Ipamorelin?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for Ipamorelin?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is Ipamorelin injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

More on Ipamorelin

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  6. 6Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  7. 7Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999PMID 10373343Accessed 2 Oct 2026
  8. 8The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
  9. 9The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001PMID 11735244Accessed 2 Oct 2026
  10. 10Drugs@FDA (openFDA) search: active ingredient "ipamorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.